Compare NVVE & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVVE | NUWE |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | 12 | 38 |
| Industry | Oil Refining/Marketing | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1M | 1.1M |
| IPO Year | N/A | N/A |
| Metric | NVVE | NUWE |
|---|---|---|
| Price | $0.32 | $3.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 214.3K | ★ 3.9M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.14 |
| Revenue Next Year | N/A | $18.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.08 |
| 52 Week High | $5.69 | $25.95 |
| Indicator | NVVE | NUWE |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 84.16 |
| Support Level | $0.22 | $2.87 |
| Resistance Level | $0.33 | $3.93 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | 0.00 | 0.38 |
| Stochastic Oscillator | 8.05 | 82.52 |
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.